|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Cyclerion Therapeutics, Inc. (CYCN) |
|
|
$0.19 0.00 (0.00%) as of 4:30 Mon 5/15
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
33,960,000 |
| Market
Cap: |
6.49(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.1912 - $0.3129 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments that restore cognitive function. Co.'s lead asset, CY6463, is central nervous system (CNS)-penetrant, soluble guanylate cyclase (sGc) stimulator that is in clinical development for Alzheimer's disease with vascular pathology (ADv), Cognitive Impairment Associated with Schizophrenia (CIAS), and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS). CY6463 is the main of its CNS portfolio with ongoing clinical programs in ADv, CIAS, and MELAS. Co.'s CNS asset, CY3018, is intended to expand the potential of sGC simulation for the treatment of disorders of the CNS.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
8 |
8 |
| Total Sell Value |
$0 |
$0 |
$27 |
$27 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
1 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wright Christopher I |
Chief Medical Officer |
• – – |
2020-12-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
45,365 |
|
-23% |
|
| Busch Andreas |
Chief Innovation Officer |
• – – |
2020-11-09 |
4 |
B |
$2.53 |
$316,250 |
D/D |
125,000 |
254,704 |
2.74 |
59% |
|
| Huyett William |
Chief Financial Officer |
• – – |
2020-11-06 |
4 |
AS |
$2.52 |
$9,644 |
D/D |
(3,827) |
67,590 |
|
61% |
|
| Greenspan David Gerald |
10% Owner |
– – • |
2020-07-29 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
6,196,063 |
|
-14% |
|
| Huyett William |
Chief Financial Officer |
• – – |
2020-02-21 |
4 |
AS |
$5.12 |
$18,222 |
D/D |
(3,559) |
71,417 |
|
26% |
|
| Currie Mark G |
President |
• – – |
2019-12-30 |
4 |
S |
$2.48 |
$62,000 |
D/D |
(25,000) |
271,755 |
|
-64% |
|
| Currie Mark G |
President |
• – – |
2019-12-27 |
4 |
S |
$2.55 |
$63,750 |
D/D |
(25,000) |
296,755 |
|
- |
|
| Busch Andreas |
Chief Innovation Officer |
• – – |
2019-11-15 |
4 |
B |
$1.82 |
$227,500 |
D/D |
125,000 |
125,000 |
2.74 |
- |
|
| Huyett William |
Chief Financial Officer |
• – – |
2019-11-08 |
4 |
AS |
$2.05 |
$8,040 |
D/D |
(3,922) |
74,976 |
|
- |
|
| Hecht Peter M |
Chief Executive Officer |
• • – |
2019-07-10 |
4 |
OE |
$6.04 |
$12,080 |
D/D |
2,000 |
225,192 |
|
- |
|
| Schulman Amy W |
Director |
– • – |
2019-04-08 |
4 |
B |
$16.00 |
$10,017,872 |
I/I |
626,117 |
21,635 |
2.1 |
- |
|
| Mcguire Terrance |
Director |
– • – |
2019-04-08 |
4 |
B |
$16.00 |
$10,017,872 |
I/I |
626,117 |
21,635 |
2.1 |
- |
|
| Currie Mark G |
President |
• – – |
2019-04-02 |
4 |
B |
$14.81 |
$4,000,285 |
D/D |
270,107 |
321,755 |
2.74 |
- |
|
| Huyett William |
Chief Financial Officer |
• – – |
2019-04-01 |
4/A |
A |
$0.00 |
$0 |
D/D |
77,492 |
78,898 |
|
- |
|
| Hecht Peter M |
Chief Executive Officer |
• • – |
2019-04-01 |
4/A |
A |
$0.00 |
$0 |
D/D |
221,736 |
221,736 |
|
- |
|
| Conrades George N |
Director |
– • – |
2019-04-01 |
4/A |
A |
$0.00 |
$0 |
D/D |
2,421 |
4,334 |
|
- |
|
| Isacson Ole |
Director |
– • – |
2019-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,421 |
2,421 |
|
- |
|
| Lovell Stephanie |
Director |
– • – |
2019-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,421 |
2,421 |
|
- |
|
| Schulman Amy W |
Director |
– • – |
2019-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,508 |
7,508 |
|
- |
|
| Huyett William |
Chief Financial Officer |
• – – |
2019-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
77,506 |
78,912 |
|
- |
|
| Fanucci Marsha |
Director |
– • – |
2019-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
16,950 |
16,950 |
|
- |
|
| Currie Mark G |
President |
• – – |
2019-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
51,648 |
51,648 |
|
- |
|
| Churchwell Kevin |
Director |
– • – |
2019-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,421 |
2,421 |
|
- |
|
| Mendelsohn Michael |
Director |
– • – |
2019-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,421 |
2,421 |
|
- |
|
| Fanucci Marsha |
Director |
– • – |
2019-04-01 |
4/A |
A |
$0.00 |
$0 |
D/D |
16,950 |
16,950 |
|
- |
|
58 Records found
|
|
Page 2 of 3 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
